Cipher Surgical Announces Mark Alley as Chief Executive Officer (CEO)

2 years ago

CHANTILLY, VA / ACCESSWIRE / March 4, 2024 / Cipher Surgical, a leading innovator in medical device technology, is pleased…

First Health Advisory Adds Health IT Leader David Finn to Deepen Digital Health Cyber Governance

2 years ago

Former CIO and CHIME leader David Finn joins First Health Advisory to support clients with policy changes facing the healthcare…

Neptune Announces Michael Cammarata’s Resignation Effective February 23, 2024

2 years ago

LAVAL, QC / ACCESSWIRE / March 4, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), today announced…

PharmaCord Announces Key Operational Appointments in Preparation for Its Next Phase of Growth

2 years ago

JEFFERSONVILLE, IN / ACCESSWIRE / March 4, 2024 / PharmaCord, a leading provider of patient services and commercialization solutions to…

Registration Is Now Open for Tribe Public’s Webinar Event “Revolutionizing Diabetes Care” Featuring Modular Medical CEO on Wednesday, March 6, 2024

2 years ago

Meet with Modular Medical CEO, Jeb BesserThere are more than 3 million individuals who use daily insulin to help with…

Ankle & Foot Centers of America Welcomes Dr. Cameron Neilson in Loganville, GA

2 years ago

Leading Podiatrist, Cameron Neilson, DPM, joins the Ankle & Foot Centers of America in Loganville, GA. Dr. Neilson is among…

Avant Brands Strengthens Board with the Addition of Tyson Macdonald

2 years ago

KELOWNA, BC / ACCESSWIRE / March 4, 2024 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU0) ("Avant" or the "Company"), a leading producer…

Intelligent Scopes Launches Helga AI-GEP™, an AI Platform for Gastroenterology with the Commencement of Validation of its AI Software Tool for Colon Cancer

2 years ago

NEW YORK and LONDON, March 04, 2024 (GLOBE NEWSWIRE) -- Intelligent Scopes Corp, specializing in state-of-the-art image enhancement and precision…

Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease

2 years ago

Encouraging preclinical studies demonstrate potential to combine AAV-ATP7A gene therapy with CUTX-101, which could be the first FDA-approved treatment for…